Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Single-use devices

This article was originally published in The Gray Sheet

Executive Summary

As of Aug. 14, all reprocessors of single-use devices (SUDs) who fail to comply with premarket and non-premarket requirements could face FDA enforcement action. Non-premarket requirements include items such as registration and listing, medical device reporting, tracking, corrections and removals, quality systems regulations and labeling. Last February, FDA granted third party reprocessors who had submitted 510(k)s a six-month grace period in which to obtain clearance for SUDs (11"The Gray Sheet" Feb. 18, 2002, p. 5). Also expired as of Aug. 14 is the grace period allowing hospitals reprocessing SUDs one extra year to come into compliance with postmarket requirements...

You may also be interested in...



Single-Use Device Reprocessor 510(k) Requirements Delayed Until Summer

FDA announced at the eleventh hour that it will extend by six months the deadline for active enforcement of premarket requirements for reprocessors of Class II single-use devices, giving the firms a Valentine's Day reprieve

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel